Human circulating B lymphocytes transformed with EBV. MH01 was derived from cell line 154 described in the reference given. No exogenous immunogen applied, antibody production was spontaneous.
| Institute |
|---|
| Medical Research Council |
| Cat. #: | 156614 |
|---|---|
| Unit size: | 100 ug |
| Target: | Human circulating B lymphocytes transformed with EBV |
| Reactivity: | Human |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | Human circulating B lymphocytes transformed with EBV. MH01 was derived from cell line 154 described in the reference given. No exogenous immunogen applied, antibody production was spontaneous. |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | None |
| Myeloma used: | NS0 |
| Target background: | Human circulating B lymphocytes transformed with EBV. MH01 was derived from cell line 154 described in the reference given. No exogenous immunogen applied, antibody production was spontaneous. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Johnson et al. 1986. J Neuroimmunol. 13(1):99-108. PMID: 2428837. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.